Home Neoplasma 2020 Neoplasma Vol.67, No.1, p.203–208, 2020

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.1, p.203–208, 2020

Title: Hepatitis B virus infection status is not associated with poor prognosis in classical Hodgkin lymphoma patients
Author: B. Bu, K. Yi, H. Wang, M. Yang, M. Wu, L. Ping, Y. Xie, J. Qiu, L. Zhao, D. Mei, X. Wang, Y. Song, J. Zhu, W. Liu

Abstract: Few studies focused on the relationship between hepatitis B virus (HBV) infection and classical Hodgkin lymphoma (cHL). This study was to evaluate the impact of HBV infection on the treatment outcome and survival of cHL patients. Clinical data of 352 cHL patients treated with ABVD regimen (doxorubicin, bleomycin, vincristine and dacarbazine) between January 2002 and January 2018 were retrospectively collected. According to HBV infection status, the patients were divided into three groups: with HBV infection [hepatitis B surface antigen (HBsAg)-positive], with past HBV infection [HBsAg-negative but anti-hepatitis B core antigen (anti-HBc)-positive], and without HBV infection (HBsAg-negative and anti-HBc-negative). The incidence of HBV infection and past HBV infection in cHL patients were 7.4% (26/352) and 16.5% (58/352), respectively. The median age of patients without HBV infection was lower than those in other two groups (p

Keywords: Hodgkin disease, hepatitis B virus, therapeutics, prognosis
Published online: 29-Jan-2020
Year: 2020, Volume: 67, Issue: 1 Page From: 203, Page To: 208
doi:10.4149/neo_2019_190211N113
Price: 12.60 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.